Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein
Open Access
- 20 May 2010
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 26 (4), 287-296
- https://doi.org/10.1002/dmrr.1080
Abstract
Background Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are novel agents for type 2 diabetes treatment, offering glucose‐dependent insulinotropic effects, reduced glucagonemia and a neutral bodyweight or weight‐reducing profile. However, a short half‐life (minutes), secondary to rapid inactivation by dipeptidyl peptidase‐IV (DPP‐IV) and excretion, limits the therapeutic potential of the native GLP‐1 hormone. Recently, the GLP‐1 receptor agonist exenatide injected subcutaneously twice daily established a novel therapy class. Developing long‐acting and efficacious GLP‐1 analogues represents a pivotal research goal. We developed a GLP‐1 immunoglobulin G (IgG4) Fc fusion protein (LY2189265) with extended pharmacokinetics and activity. Methods In vitro and in vivo activity of LY2189265 was characterized in rodent and primate cell systems and animal models. Results LY2189265 retained full receptor activity in vitro and elicited insulinotropic activity in islets similar to native peptide. Half‐life in rats and cynomolgus monkeys was 1.5–2 days, and serum immunoreactivity representing active compound persisted > 6 days. In rats, LY2189265 enhanced insulin responses during graded glucose infusion 24 h after one dose. LY2189265 increased glucose tolerance in diabetic mice after one dose and lowered weight and delayed hyperglycaemia when administered twice weekly for 4 weeks. In monkeys, LY2189265 significantly increased glucose‐dependent insulin secretion for up to a week after one dose, retained efficacy when administered subchronically (once weekly for 4 weeks) and was well tolerated. Conclusions LY2189265 retains the effects of GLP‐1 with increased half‐life and efficacy, supporting further evaluation as a once‐weekly treatment of type 2 diabetes. Copyright © 2010 John Wiley & Sons, Ltd.This publication has 23 references indexed in Scilit:
- How Our Current Medical Care System Fails People With DiabetesDiabetes Care, 2009
- The incretin system and its role in type 2 diabetes mellitusMolecular and Cellular Endocrinology, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- The Barrier of Hypoglycemia in DiabetesDiabetes, 2008
- Glycemic Control and HypoglycemiaDiabetes Care, 2008
- It's Time to Overcome Clinical InertiaAnnals of Internal Medicine, 2008
- Biology of Incretins: GLP-1 and GIPGastroenterology, 2007
- An Intervention to Overcome Clinical Inertia and Improve Diabetes Mellitus Control in a Primary Care SettingArchives of Internal Medicine, 2006
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJCI Insight, 1999
- Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.Endocrinology, 1995